Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events
Nano Letters · 2025
DOI: 10.1021/acs.nanolett.5c03454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nano Letters, 2025. Verfasst von Cai Yang und 15 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engi…. Hauptthemen laut MEDLINE: Interleukin-12, RNA, Messenger, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Themen: Patientensicherheit
Abstract (Originalsprache)
Interleukin-12 (IL-12) is a robust proinflammatory cytokine that activates immune cells, such as T cells and natural killer cells, to induce antitumor immunity. However, the clinical application of recombinant IL-12 has been limited by systemic immune-related adverse events (irAEs) and rapid degradation. To address these challenges, we employed mRNA technology to encode a tumor-activated IL-12 "lock" fusion protein that offers both therapeutic efficacy and systemic safety. Lock-IL-12 mRNA encodes a sequence consisting of the IL-12 receptor-binding domain, a matrix metalloproteinase-2 (MMP-2)-cleavable linker, and two IL-12 subunits. Systemic delivery of the mRNA via lipid nanoparticles (LNPs) enables widespread systemically expression of Lock-IL-12 protein in the locked state, and maintaining an inactive state during circulation. Upon reaching the MMP-2-rich tumor microenvironment (TME), the fusion protein undergoes cleavage, activating IL-12 to initiate a powerful antitumor immune response. This strategy represents a promising approach for cytokine-based tumor therapy, combining efficient delivery with minimal systemic toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Science and Biomedicine Laboratory (MBL), State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, College of Biology, Aptamer Engineering Center of Hunan Provi…
- The Key Laboratory of Zhejiang Province for Aptamers and Theranostics, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310022, China.
- Institute of Molecular Medicine (IMM), Renji Hospital, Shanghai Jiao Tong University School of Medicine, and College of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
ORCID-Profile: Cai Yang, Dailiang Zhang, Ding Ding, Xiangsheng Liu, Cheng Cui, Weihong Tan
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Yang, C., Zhang, L., Yang, Y., Su, M., Jiang, M., Li, J., Zhang, D., Sun, Y., Ding, D., Jia, H., Xie, S., Liu, X., Fu, T., Cui, C., Du, Z., & Tan, W. (2025). Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events. Nano Letters. https://doi.org/10.1021/acs.nanolett.5c03454
Vancouver
Yang C, Zhang L, Yang Y, Su M, Jiang M, Li J, et al. Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events. Nano Letters. 2025. doi:10.1021/acs.nanolett.5c03454
BibTeX
@article{Yang2025,
author = {Yang, Cai and Zhang, Lizhuan and Yang, Yuying and Su, Minhui and Jiang, Mengyuan and Li, Juncai and Zhang, Dailiang and Sun, Yang and Ding, Ding and Jia, Haoran and Xie, Sitao and Liu, Xiangsheng and Fu, Ting and Cui, Cheng and Du, Zhen and Tan, Weihong},
title = {Systemic Delivery of an mRNA-Encoding, Tumor-Activated Interleukin-12 Lock to Eliminate Tumors and Avoid Immune-Related Adverse Events},
journal = {Nano Letters},
year = {2025},
doi = {10.1021/acs.nanolett.5c03454}
}
EUVIMED